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E-cadherin-mediated cell-cell junctions play a
prominent role in maintaining the epithelial architec-
ture. The disruption or deregulation of these adhe-
sions in cancer can lead to the collapse of tumor
epithelia that precedes invasion and subsequent
metastasis. Here we generated an E-cadherin-GFP
mouse that enables intravital photobleaching and
quantification of E-cadherin mobility in live tissue
without affecting normal biology. We demonstrate
the broad applications of this mouse by examining
E-cadherin regulation in multiple tissues, including
mammary, brain, liver, and kidney tissue, while spe-
cifically monitoring E-cadherin mobility during
disease progression in the pancreas. We assess
E-cadherin stability in native pancreatic tissue
upon genetic manipulation involving Kras and p53
or in response to anti-invasive drug treatment and
gain insights into the dynamic remodeling of E-cad-
herin during in situ cancer progression. FRAP in the
E-cadherin-GFP mouse, therefore, promises to be a
valuable tool to fundamentally expand our under-
standing of E-cadherin-mediated events in native
microenvironments.INTRODUCTION
The capacity of cancer cells to dissociate from primary tumors
and invade requires the deregulation of interactions with adja-152 Cell Reports 14, 152–167, January 5, 2016 ª2016 The Authorscent cells and the surrounding tissue. A major challenge in
biology is the real-time monitoring of protein dynamics involved
in this process in their native context (Conway et al., 2014). The
ability to quantify the intricate spatiotemporal regulation of cell
adhesion molecules, such as E-cadherin, using techniques
including fluorescence recovery after photobleaching (FRAP)
has rapidly enhanced our understanding of E-cadherin’s subcel-
lular roles in regulating cell-cell integrity and dissociation in vitro
(Canel et al., 2010a; Shen et al., 2008; Sprague and McNally,
2005; Wu et al., 2014).
FRAP is commonly used for monitoring molecular movement
within cells. A small fluorescent region is bleached, and fluores-
cence recovery into the bleached region is measured over time
(Axelrod et al., 1976; Fritzsche and Charras, 2015; Sprague
andMcNally, 2005). From this, multiple readouts can be derived,
including, but not limited to the half-time of recovery, a measure
of the rate at which fluorescent molecules move in or out of the
region of interest, and the immobile fraction, an indication of
how much of the molecule remains trapped and unable to
move out of the analyzed region (for in-depth insights into
FRAP analysis, see Fritzsche and Charras, 2015). In the case
of fluorescently labeled E-cadherin, the immobile fraction can
indicate how much E-cadherin is trapped or engaged in cell-
cell junctions and may provide a molecular readout of junction
stability in real time (Canel et al., 2010b; Serrels et al., 2009).
FRAP has largely been used to probe molecular events within
2D cell culture using transfection-based approaches (Lippin-
cott-Schwartz et al., 2001; Shen et al., 2008), whereas its utility
in vivo has been limited (Ellenbroek and van Rheenen, 2014).
Recently, we and others have used FRAP in more complex
and physiologically relevant environments ranging from
application in Drosophila (Cavey et al., 2008) to the use of
E-cadherin-GFP FRAP in a mammalian system in vivo (Serrels
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et al., 2009), where E-cadherin-GFP-expressing squamous cell
carcinoma cells were transplanted and grown subcutaneously
in mice. Using this approach, we demonstrated that locally
invading cells had a significantly lower immobile fraction of
E-cadherin-GFP compared with non-invading cells, illustrating
that, in cancer cells that retain E-cadherin expression, mobiliza-
tion rather than loss of E-cadherin can play a role in reducing
cell-cell adhesions, leading to more malleable, motile, and inva-
sive tumor behavior (Friedl et al., 2012; Lamouille et al., 2014;
Shamir et al., 2014). Although these approaches provide in-
sights into the mobilization of E-cadherin in subcutaneous
xenograft tumors, they lack the fidelity to recapitulate the com-
plex and distinct microenvironment found in specific organs of
interest (Conway et al., 2014). It is therefore essential to
develop new tools for the quantification of molecular dynamics
in distinct organs in which the disease of interest originates,
allowing us to understand cell behavior at a subcellular and tis-
sue- and disease-specific level.
In this study, we generated a Cre-inducible E-cadherin-GFP
mouse and exploited this model using intravital FRAP imaging
to assess changes in E-cadherin-based cell-cell junction integ-
rity during disease progression and in response to drug treat-
ment. Here we mimic the disease etiology of pancreatic cancer
in situ, from acquisition of an initiating Kras mutation that
occurs in 95% of pancreatic cancers (Biankin et al., 2012; Hin-
gorani et al., 2003) to subsequent loss- or gain-of-function mu-
tations in the tumor suppressor p53, which occur in 50%–75%
of pancreatic cancers (Biankin et al., 2012). Using FRAP anal-
ysis, we reveal that E-cadherin stability in normal pancreas or
in non-invasive pancreatic tumors (KrasG12D alone or KrasG12D;
p53/) remains unaltered during disease progression. How-
ever, in mice with KrasG12D and gain-of-function mutations in
p53 (p53R172H), E-cadherin is mobilized, facilitating the weak-
ening of cell-cell contacts, correlating with the enhanced
metastasis seen in this model (Hingorani et al., 2005; Morton
et al., 2010b). Moreover, in line with recent work assessing
Src kinase as an anti-invasive drug target (Avizienyte et al.,
2002; Morton et al., 2010a; Nobis et al., 2013, 2014), we
demonstrate that the phase II drug dasatinib reverts E-cadherin
mobilization in invasive pancreatic tumors and that this stabili-
zation of junctions could partially explain its current anti-inva-
sive role in this disease (T.J. Evans et al., 2012, ASCO,
abstract). We therefore present the application of FRAP in the
E-cadherin-GFP mouse for live, tissue-specific assessment of
vital cell-cell adhesion changes in conjunction with its utility
as a pre-clinical imaging tool for evaluating the efficacy of
new therapeutics in the pancreas and other organs of interest
in real time.Figure 1. Generation of Conditional and Constitutive E-cadherin-GFP
(A) Schematic of the generation of a conditional E-cadherin-GFP OFF strain by targ
locus.
(B) Conditional E-cadherin-GFP expression in pancreas (Pdx1-Cre), liver (Cyp1a1
western Blot analyses in wild-type (WT) and transgenic organs (top band, E-cad
photon images.
(C and D) Western Blot analyses in 16 organs (C) and multiphoton images of E-cad
organs of the E-cadherin-GFP ON mouse. E-cadherin-GFP, green; SHG signal, p
See also Figure S1.
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Generation of E-cadherin-GFP Mice for In Vivo FRAP
Assessment
Conditional E-cadherin-GFP-expressing mice were generated
by targeting a lox-stop-lox transgene under the control of a
CAG promoter into the deleted Hprt locus of HM1 embryonic
stem (ES) cells (Figure 1A; Bronson et al., 1996). We first gener-
ated E-cadherin-GFP ‘‘OFF’’ mice, a strain in which expression
of the extensively validated EGFP-linked E-cadherin fusion pro-
tein (Lock and Stow, 2005) was conditionally prevented by a
transcriptional stop sequence (Figure 1A). To demonstrate the
utility and scope of the E-cadherin-GFP mouse for examining
the regulation of E-cadherin in different organs, we crossed
E-cadherin-GFP OFF mice to tissue-specific Cre strains to
induce organ- and cell-type-specific expression in the
pancreas (the focus of this study), liver, mammary gland, and
pancreatic islets (Figure 1B). Expression of E-cadherin-GFP in
the pancreas via Pdx1-Cre could be imaged readily at depth
(Movie S1, first panel; green, E-cadherin-GFP; purple, second
harmonic generation [SHG] imaging of the extracellular matrix
[ECM]). In the liver, E-cadherin-GFP OFF mice were crossed
to Cyp1a1-Cre mice (Ireland et al., 2004), and deletion of the
stop cassette was achieved after three doses of 2 mg b-naph-
thoflavone over 8 hr (Movie S1, second panel). Robust expres-
sion in mammary tissue via MMTV-Cre (Wagner et al., 1997)
was imaged in the alveoli of lactating mice where junction
integrity is required during milk production (Movie S1, third
panel; Figures S1A and S1B), whereas sub-organ specificity
within islet cells of the pancreas via RIP-Cre (Postic et al.,
1999) could be demonstrated in isolated pancreatic islets
(Movie S1, fourth panel).
Conditional E-cadherin-GFPmice were subsequently crossed
tomice expressing CMVCre recombinase (Schwenk et al., 1995)
to enable constitutive, low-level expression of E-cadherin-GFP
in every tissue (Figure 1C). Analysis of E-cadherin in multiple tis-
sue types from the E-cadherin-GFP ‘‘ON’’ mouse illustrates the
broader capacity for subcellular FRAP imaging in normal or dis-
ease contexts of interest (Figure 1D; Movie S2, left panels, kid-
ney, brain and salivary gland; right panels, pancreas, liver, and
mammary tissue). Importantly, mice of both E-cadherin-GFP
strains were born at the expected Mendelian ratio, were fertile
and healthy, and exhibited no untoward behaviors. In this study,
we demonstrate the application of photobleaching in the E-cad-
herin-GFP mouse as a method for assessing the subcellular
regulation of E-cadherin in the progression of invasive pancreatic
cancer. However, this system could be used in other disease
states in future investigations.Mice
eting a lox-stop-lox transgene under the control of a CAG promoter to theHprt
-Cre), mammary gland (MMTV-Cre), and pancreatic islets (RIP-Cre). Shown are
herin-GFP; bottom band, endogenous E-cadherin) and corresponding multi-
herin GFP expression (D, column 1) and confocal FRAP (D, columns 2–4) in six
urple; red arrow, bleach point.
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FRAP Assessment of E-cadherin in Two versus Three
Dimensions Reveals Mobilization Differences between
Non-invasive and Invasive Pancreatic Cancer
Prior to generation of the E-cadherin-GFPmouse, we first estab-
lished primary non-invasive pancreatic tumor cell lines from
Pdx1-Cre; KrasG12D/+; p53flox/+ mice (Morton et al., 2010b) in
which the wild-type p53 allele is lost (hereafter referred to as
p53/). Using these cells, we generated stable pancreatic
ductal adenocarcinoma (PDAC) p53/ cells expressing empty
vector alone (p53/ vector) or the human equivalent of murine
p53R172H (p53/ R175H) with E-cadherin-GFP (Muller et al.,
2013; Tan et al., 2014). The resulting invasive mutant p53/
R175H and non-invasive p53/ vector cells expressing E-cad-
herin-GFP (Figure 2A; Movie S3) serve as a fluorescent model
system to gauge the initial spatiotemporal regulation of E-cad-
herin in pancreatic cancer (Morton et al., 2010b; Muller et al.,
2013; Tan et al., 2014) without affecting fundamental processes
such as cell proliferation or invasive capacity (Figures S1C and
S1D).
FRAP recovery curves from time-lapse movies of p53/ vec-
tor or p53/ R175H primary PDAC cells were then analyzed
(Canel et al., 2010a, 2010b; Serrels et al., 2009; Vlahov et al.,
2015; Supplemental Experimental Procedures; Figure S2).
Assessment in two dimensions revealed no difference in E-cad-
herin mobility of invasive p53/ R175H versus non-invasive
p53/ vector cells (Figure 2B, blue recovery curve versus
green), where the fraction of E-cadherin-GFP stabilized in cell-
cell junctions was similar in both cell types (Figure 2C, mobile
fraction 45.6% ± 2.7% for p53/ vector compared with 46%
± 3.1% for p53/ R175H cells).
Critically, assessment in a 3D environment using cells grown
on cell-derived matrices (CDMs) to mimic in vivo conditions
(Herrmann et al., 2014; Yamada and Cukierman, 2007) revealed
enhanced mobilization of E-cadherin in invasive cells, where
mutant p53/ R175H cells had a significantly higher mobile
fraction of E-cadherin compared with p53/ vector cells (Fig-
ures 2B, orange recovery curve versus purple, and2C, average
mobile fraction 39.9%± 2.8%versus 65.6%± 4.4%;Figure S3A).
This is in line with the early cell-cell dissociation preceding cell
scattering and invasion we observed recently in mutant p53 cells
compared with p53/ cells (Muller et al., 2013; Tan et al., 2014)
and highlights the need to assess E-cadherin cell-cell adhesion
events in a 3D context.
To further assess E-cadherin mobility and corroborate our
findings in this 3D setting, complementary fluorescence loss in
photobleaching (FLIP) analysis was performed on p53/ vector
versus mutant p53/ R175H cells grown on CDMs (FiguresFigure 2. E-cadherin Junctions Are Mobilized in Three Dimensions in I
(A) Representative images from confocal FRAP movies of non-invasive p53/ ve
bleached regions.
(B and C) FRAP recovery curves (B) and mobile fraction plots (C) comparing E-cad
in a 2D versus 3D environment. n = 3, >10 junctions/group.
(D) Representative images from FLIP movies of p53/ vector (top) and p53/ R1
tracked bleached junctions; blue lines, tracked adjacent junctions; orange lines,
(E) Photobleach-corrected kymographs showing the intensity profile along the b
(F andG) Photobleach-corrected, normalized intensity profiles (F) and averaged fra
and distant junctions (orange) of p53/ vector (light colors, n = 13) and p53/ R
Columns, mean; bars, ± SE. *p < 0.05; **p < 0.01; ***p < 0.001. ns, not significan
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bleaching an area within a cell-cell junction, we observed that,
in p53/ vector cells, junctions adjacent to the bleached region
did not significantly reduce fluorescence intensity over the time
course of our FLIP analysis after correcting for imaging-induced
photobleaching (Figures 2D and 2E; Movie S4 [the white rect-
angle indicates a repeated bleach region, and red, blue, and or-
ange lines represent bleached, adjacent, and distant non-related
control junctions, respectively]). Here, FLIP traces of adjacent
junctions (Figures 2F and 2G, light blue line and bar graph)
show no significant reduction in intensity over the 800-s time
course. In contrast, mutant p53/ R175H cells exhibited a sig-
nificant loss of fluorescence intensity in junctions adjacent to
the bleach region over time (Figures 2F and 2G, dark blue line
and bar graph), commensurate with the transfer of bleached
E-cadherin molecules into this area and an enhanced mobiliza-
tion of E-cadherin junctions in mutant p53 cells compared with
p53/ vector cells.
To assess whether E-cadherin is distributed equally at distinct
points of the membrane in PDAC cells, we created kymographs
of unbleached junctions from p53/ vector and p53/ R175H
cells (Figures S3B–S3D). We observed an elevated distribution
of high-intensity zones of E-cadherin-GFP in p53/ vector cells
compared with p53/ R175H cells (Figures S3C and S3D, blue
arrows). These zones persisted over the time course of imaging
and could represent stable E-cadherin zones, as identified previ-
ously by others (Adams et al., 1998; Cavey et al., 2008). To quan-
tify the uniformity or texture of this E-cadherin intensity across
the membrane, we used orientation-dependent grey level co-
occurrence matrix (OD-GLCM) analysis of the kymographs
(Figure S3B; Hu et al., 2012; Nobis et al., 2013). This analysis re-
vealed that the inherent distribution of high-intensity E-cadherin-
GFP zones was significantly different between p53/ vector
and p53/ R175H junctions (quantified as contrast in Fig-
ure S3E), indicating a larger number of zones of high E-cadherin
intensity in non-invasive p53/ vector cells. Collectively, these
data support our initial FRAP results, revealing a critical mobiliza-
tion of E-cadherin in mutant p53 cells in 3D in vitro settings.
PDAC cells were therefore injected into CD1 nudemice and al-
lowed to form subcutaneous tumors. In line with previous work
(Muller et al., 2013; Timpson et al., 2011), p53/ R175H tu-
mor-bearing mice demonstrated collective local invasion
comparedwith encapsulated non-invasive p53/ vector tumors
(Figure 3A). FRAP recovery curves from time-lapse movies of
xenograft tumors obtained using intravital FRAP imaging (Fig-
ure 3B) revealed an enhanced mobile fraction in p53/ R175H
versus p53/ vector cells in this setting (Figures 3C and 3D,nvasive PDAC Cells
ctor (top) versus invasive p53/ R175H cells (bottom) grown on CDM. Arrows,
herin-GFPmobilization between p53/ vector and p53/ R175H cells grown
75H cells (bottom) grown on CDM. White rectangles, bleach regions; red lines,
distant control junctions.
leached junction over time. White arrows, bleach events.
ction of fluorescence retained after 800 s (G) for bleached (red), adjacent (blue),
175H cells (dark colors, n = 14).
t (unpaired Student’s t test). See also Figures S2 and S3.
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32.1% ± 2.9% versus 18.8% ± 1.7%; Figure S3F; Movie S5).
Similarly, FLIP analysis of the xenograft tumors (Figures 3E–
3H; Movie S6) shows a significantly higher loss of fluorescence
in areas proximal to the bleach region in p53/ R175H tumors
compared with p53/ vector tumors, corroborating our FRAP
analysis (Figures 3G and 3H, compare light blue and dark blue
FLIP traces and bar graphs). Furthermore, OD-GLCM analysis
of unbleached junctions again showed a higher contrast
of high versus low E-cadherin-GFP intensity/texture in p53/
vector tumors compared with p53/ R175H tumors (Figures
S3G–S3I), indicating an increased stabilization of E-cadherin in
p53/ vector control cells in vivo.
To further investigate the differences in E-cadherin mobility
between p53/ vector and p53/ R175H tumors, we bleached
a large region of interest with a 3-mm diameter. The change in in-
tensity profile along themembrane of a large FRAP bleach region
over time can provide insights into the processes governing re-
covery (modeled in Figures 4A and 4B). We therefore generated
kymographs of the bleached junction and measured the fluores-
cence intensity along the junction via line scan analysis at
defined time points (Figures 4C and 4F, colored arrowheads;
de Beco et al., 2012; Delva and Kowalczyk, 2009). We then fitted
the results of our line scan analysis to a Gaussian curve model
(Figures 4D and 4G) and plotted the decrease in width of the
Gaussian curves over time as a measure of the speed of fluores-
cence recovery (Figures 4E and 4H). If the recovery was due to
lateral movement in the membrane, then the width of the
bleached region should increase linearly with time (Figure 4A).
Conversely, if the recovery was due to cytoplasmic uniformed
exchange, then the width of the bleached region should remain
uniform with time (Figure 4B). Here we find that the width of
the bleached region expands significantly faster in p53/
R175H xenografts compared with p53/ vector xenografts,
indicating faster lateral motion of E-cadherin in the mutant xeno-
grafts (Figures 4C–4H; compare the slopes as a measure of the
recovery speed between Figures 4E and 4H, with the effective
diffusion coefficient Deff = 4.88 ± 0.3 3 10
3 mm2 s1 versus
1.70 ± 0.1 3 103 mm2 s1, respectively). This indicates that
the increase in E-cadherin mobility observed in locally invasive
p53/ R175H xenografts may be primarily attributed to
increased mobility within the membrane.
Although this subcutaneous model confirmed that enhanced
mobilization of E-cadherin exists in live 3D tumor settings, it
does not recapitulate the distinct microenvironment found in
the pancreas. This prompted us to investigate whether subcellu-Figure 3. FRAP and FLIP in Live Tumors Reveal E-cadherin Mobilizatio
(A) Representative images of encapsulated p53/ vector tumors (left, dashed
arrows).
(B) Representative images from confocal FRAP movies of p53/ vector (top) ve
(C and D) FRAP recovery curves (C) and mobile fraction plots (D) comparing E-cad
in a 2D versus 3D environment. n = 3, >10 junctions/group.
(E) Representative images from FLIP movies of p53/ vector (top) and p53/ R
bleached junctions.
(F) Photobleach-corrected kymographs showing the intensity profile along the b
(G and H) Photobleach-corrected, normalized intensity profiles (G) and averaged
areas 3 mmdistant from the bleached region (blue), and distant control junctions (o
n = 5).
Columns, mean; bars, ± SE; n = 3 mice; >5 cells/group. *p < 0.05; **p < 0.01 (un
158 Cell Reports 14, 152–167, January 5, 2016 ª2016 The Authorslar mobilization of E-cadherin occurs in the organ of tumor origin
and, if so, whether the stage of in situ disease progression in
which these changes occur can be identified (Bardeesy and
DePinho, 2002).
FRAP in the E-cadherin-GFP Mouse Reveals Genetically
Driven Progression of Cell-Cell Junction Disruption in
Pancreatic Tissue during In Situ Disease Development
Our ability to use FRAP in vivo led us to investigate whether we
can assess E-cadherin mobility in live pancreatic tissue. The
E-cadherin-GFP mouse was therefore crossed with either wild-
type mice expressing Pdx1-Cre, mice bearing a Pdx1-Cre-
driven initiating KrasG12D mutation alone, Pdx1-Cre; KrasG12D;
p53/ mice, or Pdx1-Cre; KrasG12D; mutant p53R172H mice
and monitored for 150 days to allow tumor formation to occur.
This allowed us to recapitulate the genetic changes commonly
occurring during the formation of invasive PDAC (Figures 5A–
5C; Movie S7) in this extensively validated model of pancreatic
cancer.
FRAP recovery curves from time-lapse movies of wild-type
E-cadherin-GFP mice (Figure 5D, green line) were analyzed to
gauge the inherent mobility of E-cadherin in normal pancreatic
tissue (Figure 5E, average mobile fraction = 21.9% ± 1.6%; Fig-
ure S4A). Interestingly, the fraction of E-cadherin stabilized in
cell-cell junctions in wild-type mice was similar to that of non-
invasive tumors bearing KrasG12D (Figures 5D and 5E, blue line,
mobile fraction = 24.3% ± 2.3%). This indicates that initiating
KrasG12D mutations in the pancreas are not sufficient to drive
E-cadherin mobilization in situ.
Importantly, loss of p53 on a KrasG12D background from age-
matched tumors also had no effect on E-cadherin mobility
compared with normal pancreatic tissue or KrasG12D tumors
alone (Figures 5D and 5E, purple line, 21.6% ± 1.7%mobile frac-
tion). This demonstrates that, although loss of the tumor sup-
pressor p53 in combination with initiating KrasG12D mutations
enhances tumor progression, it does not act to mobilize E-cad-
herin, correlating with the lack of invasion or metastasis we
observed previously in KrasG12D; p53/ mice (Morton et al.,
2010b).
Critically, FRAP analysis of tumors from 150-day-old,
KrasG12D; p53R172H; E-cadherin-GFP mice revealed that gain-
of-function mutations in p53 on a KrasG12D background signifi-
cantly mobilizes E-cadherin junctions in the pancreas (Figures
5D and 5E, orange line, 31.8% ± 1.8%mobile fraction compared
with the average of 22.4% ± 1.1% found in normal pancreas,n during Invasion
line, black arrows) versus locally invasive p53/ R175H tumors (right, white
rsus p53/ R175H xenografts (bottom). Red arrows, bleached regions.
herin-GFPmobilization between p53/ vector and p53/ R175H cells grown
175H xenografts (bottom). White rectangles, bleach regions; red lines, tracked
leached junction over time. Arrows, bleach events.
fraction of fluorescence retained after 400 s (H) for the bleached region (red),
range) of p53/ vector (light colors, n = 9) and p53/R175H cells (dark colors,
paired Student’s t test). See also Figures S2 and S3.
A B
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Figure 4. Large-Area E-cadherin-GFP FRAP in PDAC Xenografts
(A, B, C, and F)Models of recovery via lateral membrane diffusion (A) and via cytoplasmic exchange (B) with line profiles along the bleached region during recovery
(early time points, blue; late time points, red) and simulated intensity kymographs. Black arrows highlight changes in recovery (C and F). Also shown is a
normalized average kymograph for large-region FRAP of p53/ vector (C, n = 9) and p53/R175H (F, n = 9) xenografts. Colored arrowheads indicate time points
where profiles were fitted and shown in later plots (early time points, blue; late time points, red). Dashed black areas, bleached regions.
(D and G) Line profiles from recovery (early time points, blue; late time points, red) with fitted Gaussian curves (solid lines).
(E and H) Fitted width (s2) of Gaussian curves for selected time points, with linear fit (gray line) used to calculate the diffusion coefficient (slope). Error bars,
confidence interval on fitted parameter.KrasG12D, or KrasG12D; p53/ tumors). This indicates that acqui-
sition of mutant p53R172H, which we have shown previously to
drive an invasive and metastatic program over and above the
loss of p53 in pancreatic cancer (Morton et al., 2010b), could
partially achieve this by allowing early tumor dissolution via
mobilization of E-cadherin-based cell-cell contacts (Figure 5F).
Therefore, we sought to assesswhether this potentially pro-inva-
sive molecular event could be impaired pharmacologically and
monitored in a pre-clinical setting using the E-cadherin-GFP
mouse.
The E-cadherin-GFP Mouse as a Tool to Monitor Early
Anti-invasive Drug Response in Real Time
Recently we demonstrated that Src kinase, which is known to
induce the disruption of E-cadherin-based cell-cell junctions
either directly (Avizienyte et al., 2002; Calautti et al., 1998; Frame
et al., 2002) or indirectly via the stroma (Yang et al., 2010), plays aCprominent role in invasive pancreatic cancer (Morton et al.,
2010a). We therefore examined whether the mobilization and
potential weakening of E-cadherin junctions observed in invasive
pancreatic tumors of Pdx1-Cre; KrasG12D; p53R172H E-cadherin-
GFP mice could be reverted using dasatinib.
As before, Pdx1-Cre; KrasG12D; p53R172H; E-cadherin-GFP
micewere allowed to form tumors for150 days and, upon signs
of tumor burden, were placed on daily dasatinib treatment
(10 mg/kg) for 3 consecutive days (Figure 6A), followed by
FRAP analysis (Figure 6B; Movie S7). This revealed that rever-
sion of E-cadherin mobilization back to the levels found in
wild-type pancreas or non-invasive KrasG12D; p53/ tumors
could be achieved using dasatinib treatment at this stage of
the disease (Figures 6C and 6D, compare mobile fraction of
KrasG12D; p53R172H mice ± dasatinib, 18.1% ± 1.3% versus
31.8% ± 1.8%, and 5E, KrasG12D alone or KrasG12D; p53/, mo-
bile fraction of 24.3% ± 2.3% and 21.6% ± 1.7%; Figure S4B).ell Reports 14, 152–167, January 5, 2016 ª2016 The Authors 159
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Figure 5. E-cadherin-GFP FRAP during Tissue Homeostasis, Initiation, and Progression of Pancreatic Cancer
(A) Proposed pancreatic cancer progression model from initiating Kras mutations (PanIN) to subsequent loss of p53 or gain-of-function mutations in p53.
(B) Representative whole-body image of an E-cadherin-GFPmousewithmultiphoton-based cell-cell junction imaging (inset: E-cadherin-GFP, green; SHG signal,
purple).
(C) Representative images from confocal FRAP movies in the E-cadherin-GFP mouse from normal pancreas (first row) to acquiring KrasG12D (second row) with
subsequent loss of p53 (third row) or p53R172H gain-of function mutations (bottom row), respectively. Red arrows, bleached regions.
(D and E) Graphs comparing E-cadherin-GFPmobilization between in situ pancreatic tissue from normal (green), KrasG12D alone (blue), KrasG12D; p53/ (purple),
and KrasG12D; p53R172H (orange) mice. Columns, mean; bars, ± SE, n = 3 mice/group,R21 junctions in total. *p < 0.05 (unpaired Student’s t test).
(F) Proposed schematic of E-cadherin dynamics during PDAC progression.
See also Figure S4.These results indicate that the recently demonstrated efficacy of
dasatinib in this model could partly be due to its capacity to sta-
bilize E-cadherin junctions and prevent dissociation from the pri-160 Cell Reports 14, 152–167, January 5, 2016 ª2016 The Authorsmary tumor. We therefore sought to determine whether the
E-cadherin-GFP FRAP readouts we observed in this study could
be correlated with changes in junction integrity and strength.
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Figure 6. The E-cadherin-GFP Mouse as a Tool to Monitor the Early Anti-invasive Drug Response
(A) Schematic of anti-invasive dasatinib treatment using KrasG12D; p53R172H; E-cadherin-GFP mice.
(B) Representative images from confocal FRAP movies of dasatinib-treated KrasG12D; p53R172H; E-cadherin-GFP mouse (oral gavage, 33 daily, 10 mg/kg). Red
arrows, bleached regions.
(C and D) Graphs comparing E-cadherin-GFP mobilization in in situ pancreatic tissue of control (orange) and dasatinib-treated (pink) KrasG12D; p53R172H;
E-cadherin-GFP mice. Columns, mean; bars, ± SE; n = 3 mice/group,R21 junctions in total. **p < 0.01 (unpaired Student’s t test).
(E and F) TEER (E) and Dispase assays (F) in E-cadherin-GFP-transfected p53/ PDAC cells (columns 1 and 3, pre-dasatinib; columns 5 and 7, post-dasatinib)
versus mutant p53 PDAC cells (columns 2 and 4, pre-dasatinib; columns 6 and 8, post-dasatinib). Columns, mean; bars, ± SE; n = 3 mice/group. *p < 0.05;
**p < 0.01 (unpaired Student’s t test).
See also Figure S4.
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Using complementary assays, we interrogated the integrity
and strength of cell-cell junctions using trans-endothelial elec-
trical resistance (TEER) and Dispase II assays, respectively
(Calautti et al., 1998; Canel et al., 2010b; von Bonsdorff
et al., 1985). TEER allows a rapid evaluation of junction integ-
rity as a function of electrical resistance between cells where
high resistance correlates with high junction integrity (von
Bonsdorff et al., 1985). Examination of the electrical resistance
between non-invasive p53/ and invasive p53R172H cells
transfected with E-cadherin-GFP demonstrated that junction
integrity was significantly lower in a mutant p53R172H back-
ground than in a p53/ setting (Figure 6E, columns 1 and 2).
Similar results were obtained in E-cadherin-GFP-transfected
p53/ R175H and p53/ vector cells (Figure 6E, columns
3 and 4), confirming that mutant p53 reduces junction integrity
in PDAC cells.
In line with our results demonstrating that dasatinib impairs in-
vasion via potentially enhancing cell-cell adhesions, TEER anal-
ysis of dasatinib-treated mutant p53-expressing PDAC cells
(E-cadherin-GFP-transfected p53R172H or p53/ R175H cells)
revealed that Src inhibition (Figures S4D and S4E) stabilized
and strengthened junctions to a similar level as that found in a
non-invasive p53/ setting (Figure 6E, columns 5–8). This was
confirmed using the Dispase II assay, where mutant p53 cells
(E-cadherin-GFP-transfected p53R172H or p53/ R175H cells)
show an increased number of single cells upon mechanical
disruption compared with p53/ E-cadherin-GFP-transfected
counterparts (Figure 6F, columns 1–4). Importantly, cell dissoci-
ation was reverted to similar levels as those found in non-inva-
sive p53/ or vector-alone counterparts when mutant p53 cells
were treated with dasatinib (Figure 6F, compare columns 1–4
with columns 5–8). These results illustrate that mutant p53 on
an initiating KrasG12D background weakens cell-cell junction
strength, which could lead to tumor dissociation, and that Src in-
hibition can partially impair this breakdown. Importantly, we
corroborated these finding with another Src inhibitor, saracate-
nib (Figures S4D and S4E; Nam et al., 2013), and observed a
similar strengthening and enhancement of junction integrity via
TEER and Dispase II analysis (Figures S4F and S4G), with a cor-
responding stabilization of E-cadherin mobility, as assessed by
FRAP on CDMs (Figure S4C). These data, therefore, demon-
strate that imaging subtle changes in the mobility of proteins
involved in maintaining normal epithelial architecture, such as
E-cadherin, can provide a surrogate marker of dissociation
events that may precede the collapse of cell-cell adhesions,
correlating with tumor cell invasion.
Monitoring E-cadherin Dynamics in Secondary
Metastases
In line with the concept of stabilizing E-cadherin junctions via Src
inhibition, we isolated metastatic tumor cells that had colonized
the liver of invasive Pdx1-Cre; KrasG12D; p53R172H; E-cadherin-
GFP mice using whole-body fluorescence imaging (Figures 7A
and 7B, whole-body imaging and inset, respectively, showing
primary tumor and liver micro-metastases isolated from the
same mouse). We confirmed that metastatic cells from the
E-cadherin-GFP mouse retained similar E-cadherin expression
levels as cell lines obtained from primary tumors, and similar162 Cell Reports 14, 152–167, January 5, 2016 ª2016 The Authorslevels of proliferation (Figures 7C–7E, Figures S5A and S5B),
while maintaining the capacity to invade in 3D organotypic
matrices (Figures 7F, 7G, and S5C, left). Importantly, upon treat-
ment of these invasive cells with dasatinib, invasionwas reduced
significantly compared with control cells (Figures 7F, 7G, and
S5C, right, for three independent metastatic lines from three in-
dependent mice [101912 met, 101025 met, and 111375 met,
respectively]). Moreover, the integrity of cell-cell contacts in all
lines was partially restored under dasatinib-treated conditions,
leading to enhanced cell-cell clustering (Figures 7F, 7G, and
S5C). Subcellular immunofluorescent staining of E-cadherin
showed improved cell clustering in cells treated with dasatinib
(Figures 7H, 7I, and S5D, red arrows). Importantly, we observed
a similar reduction in invasion and a restoration in junction integ-
rity for all three metastatic cell lines treated with saracatenib in
organotypic assays (Figure S6A–S6E). Collectively, these data
indicate that Src inhibition may partially stabilize E-cadherin-
based cell-cell junctions and could retard early pancreatic tumor
cell dissociation and, subsequently, decrease invasive efficiency
by inducing tumor cell clustering.
This led us to examine whether the enhanced mobilization of
E-cadherin and weakening of junction strength observed in
invasive mutant p53 pancreatic tumors (Figures 3 and 5) could
also be partly reverted in these more aggressive metastatic
lines from the E-cadherin-GFP mouse. As before, TEER and
Dispase II assays were carried out, and, in all three metastatic
lines, a significant enhancement in junction integrity and
strength was observed following dasatinib treatment (Figures
7J, 7K, and S5E). Again, similar effects on TEER and Dispase
II analysis were observed upon saracatenib treatment in all
three metastatic cell lines (Figures S6F–S6H). In contrast, dasa-
tinib and saracatenib treatment had no effect on junction integ-
rity and strength in primary tumor cells isolated from Pdx1-Cre;
KrasG12D; p53/; E-cadherin-GFP mice (Figures S5F and S6I),
which inherently possess high junction strength and integrity.
Lastly, in line with our CDM and xenograft data (Figures 2
and 3), OD-GLCM analysis of mutant metastatic lines also re-
vealed a reduction in contrast and a more uniform, malleable
organization of E-cadherin-GFP distribution compared with pri-
mary tumor cells isolated from Pdx1-Cre; KrasG12D; p53/;
E-cadherin-GFP mice (Figures S6J and S6K), suggesting that
E-cadherin destabilization is maintained in mutant p53 meta-
static cells derived from the E-cadherin-GFP mouse. Collec-
tively, these results highlight the utility of the E-cadherin-GFP
mouse as a pre-clinical imaging tool for monitoring early sub-
cellular molecular changes that correlate with more aggressive
tumor behavior.
DISCUSSION
Downregulation or loss of E-cadherin expression occurs in a
number of cancer types and is thought to play a key role in
epithelial-to-mesenchymal transition (EMT) associated with
invasive cancer phenotypes (Gregory et al., 2008; Lamouille
et al., 2014). However, in many invasive cancers, including
pancreatic cancer, E-cadherin expression is often retained
(David and Rajasekaran, 2012; Shamir et al., 2014) and utilized
positively during cancer progression (Campbell and Casanova,
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(legend on next page)
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2015; Wicki et al., 2006). This indicates that, in many cases,
deregulation of E-cadherin mobility rather than expression level
may play an additional role in promoting invasion and suggests
that monitoring E-cadherin behavior in this context could lead
to a greater understanding of cancer invasion and response to
new therapeutics (Wicki et al., 2006). Here, we present the gen-
eration of an E-cadherin-GFP mouse in which E-cadherin
behavior can be monitored within intact tissues, such as the
pancreas, liver, brain, kidney, and mammary tissue, via FRAP.
Using this mouse in the context of pancreatic cancer, we reveal
significant biological insights into the in situ regulation of E-cad-
herin during normal tissue homeostasis, disease initiation, and
progression of pancreatic cancer while highlighting its potential
utility for monitoring drug target activity in vivo using FRAP.
We chose the Hprt locus to drive E-Cadherin-GFP expression
to provide the best signal-to-noise ratio for intravital imaging
while aiming to minimize disturbance to early developmental
events, such as tissue sorting (Halbleib and Nelson, 2006), and
normal tissue function. Our assessment of the E-cadherin-GFP
mouse, in the context of the comprehensively characterized
KrasG12D/+; Trp53R172H/+; Pdx1-Cre (KPC) mouse model of
pancreatic cancer, suggests that we gauged expression levels
well, providing enough fluorescence for detection of pre- and
post-photobleaching events without affecting primary tumor
growth and metastasis. This is in line with our recent develop-
ment of the Rac-Fo¨rster resonance energy transfer (FRET)
biosensor mouse in which low-level expression driven via the
ROSA26 locus provided a sufficient signal for in vivo FRET imag-
ing during disease progression without affecting the biology of
the cells (Johnsson et al., 2014).
Crossing the E-cadherin-GFP mouse with distinct genetic
models of pancreatic cancer has demonstrated its utility for
examining the effects of specific mutations on E-cadherin in a
time- and tissue-specific and subcellular manner. In pancreatic
cancer, initiating mutations in the KRAS gene occur in approxi-
mately 95% of patients and are often followed by sequential
accumulation of genetic alterations, such as loss of expression,
function, or mutations in tumor suppressors and regulators, such
as TP53, CDKN2A, INK4A/ARF, and/or PTEN (Bardeesy and
DePinho, 2002; Kennedy et al., 2011; Ling et al., 2012; Morran
et al., 2014). Although we know the frequency of such mutations
in PDAC (Biankin et al., 2012), their specific function during
development of invasive pancreatic cancer remains unclear.
Here, we show that acquiring KrasG12D mutations or subsequent
loss of p53 on a KrasG12D background in the pancreas is not suf-
ficient to drive alterations to E-cadherin mobility, whereas acqui-Figure 7. Monitoring E-cadherin Dynamics in Secondary Metastases f
(A and B) Whole-body image of primary tumor (A) (B, white arrows) and isolated liv
arrow). Blue arrow, auto-fluorescence in the bile duct.
(C–E) Western blot (C, top band, E-cadherin-GFP; bottom band, endogenous E-c
lines 101912 and 111375 (D) and 105925 (E).
(F and G) The isolated metastatic cell lines 101912 met (F) and 105925 met (G) fr
dasatinib (13 days, 200 nM). Black arrows, cluster formation upon dasatinib treatm
clustering within matrices ± dasatinib.
(H and I) Immunofluorescence staining of E-cadherin within matrices ± dasatinib fo
within cell clusters upon dasatinib treatment. E-cadherin, green; DAPI, blue.
(J and K) TEER (left) and Dispase assays (right) in metastatic lines derived from t
Columns, mean; bars, ± SE; n = 4 mice/group. *p < 0.05 (unpaired Student’s t te
164 Cell Reports 14, 152–167, January 5, 2016 ª2016 The Authorssition of a gain-of-function mutation in p53 on the same initiating
KrasG12D background mobilizes E-cadherin, consistent with the
tumor dissolution and metastasis found in these mice.
Importantly, reduction or reversion of cell-cell junction
strength was achieved by molecular manipulation in the form
of overexpressing the human equivalent of murine p53R172H
(R175H) or inhibiting E-cadherin mobilization via Src inactivation,
respectively. This demonstrates that mutant p53 can partially
drive the breakdown of tumors by disrupting E-cadherin cell-
cell engagement via Src. It should be noted that both dasatinib
and saracatenib, while inhibiting Src kinase, also target Abl
and other kinases (Haubeiss et al., 2010) and were used here
in a proof-of-principle context to demonstrate the utility of the
mouse in pre-clinical drug discovery applications. To this end,
the E-cadherin-GFPmouse could also be used to decipher other
molecular pathways downstream ofmutant p53 to be targeted in
future studies or be used with other Kras or p53 mutations to
determinewhether E-cadherinmobilization is a general phenom-
enon for all mutant p53 variants in this disease (Muller et al.,
2009, 2013; Muller and Vousden, 2014).
It is important to note that, in this study, we examined E-cad-
herin-GFP mobility throughout the entire pancreatic tumor tis-
sue. However, heterogeneity is a hallmark of in vivo cancer,
and it will be possible, in the future, to map areas of weakened
cell-cell adhesions or drug response in the KPC model by
examining E-cadherin mobilization in the center versus the
invasive front of the tumor (Serrels et al., 2009). Similarly, the
drug response in cancer cells in relation to local blood or
drug supply could be assessed, as we and others have
described previously (Manning et al., 2013; Nobis et al.,
2013). In this way, we could determine, in the future, whether
spatially regulated environmental cues in the native pancreas
drive this heterogeneity or reflect a gradient in anti-invasive
drug response in vivo.
Finally, the intricate control of in vivo distribution, function, as
well as potential redundancy of EMT regulators such as Snail,
Slug, Zeb, or Twist (Brabletz et al., 2013) could be investigated
in pancreatic or other cancer types using the E-cadherin-GFP
mouse. This could help dissect, in real time, the complex
changes in E-cadherin mobility that occur during EMT, which,
in many cases, does not involve loss of E-cadherin expression
but rather a more complex dynamic regulation and utilization
of E-cadherin function (David and Rajasekaran, 2012; Shamir
et al., 2014; Wu et al., 2015).
The location, signaling, and dynamics of E-cadherin in
the context of the surrounding environment can play a vital rolerom the E-cadherin-GFP Mouse
er micro-metastases of a KrasG12D/+; p53R172H; E-cadherin-GFP mouse (B, red
adherin) and quantification (D and E) in isolated the primary and metastatic cell
om the liver of the E-cadherin-GFP mouse invading in organotypic matrices ±
ent. Shown is the quantification of cell invasion between 200–400 mm and cell
r the metastatic lines 101912met (H) and 105925met (I). Red arrows, junctions
ransgenic mouse, 101912 met (J), and 105925 met (K) ± dasatinib.
st). See also Figures S5 and S6.
in disease progression. Our capacity to isolate and image micro-
metastases in the liver illustrates the power of this model for
assessing subcellular changes in E-cadherin dynamics at sec-
ondary tumor sites that retain E-cadherin expression and may
take advantage of this existing pool of E-cadherin during the early
stages of mesenchymal-to-epithelial transition (MET) and tumor
colonization (Lamouille et al., 2014; Ocan˜a et al., 2012). EMT-to-
MET switching during extravasation and colonization is thought
to be controlled precisely and has significant implications on
whether anti-invasive drug targeting will be effective in impairing
subsequent tumor colonization of the primary tumor in secondary
sites (Brabletz et al., 2013). Preventing niche localization at the
early stage of colonization by using anti-migratory drug targeting
has been shown recently to be an effective strategy in impairing
metastasis formation in the liver (Ritsma et al., 2012). However,
understanding when and where EMT versusMET are detrimental
or conducive to tumor extravasationwill be of great interest in the
future (Brabletz et al., 2013). Therefore, FRAP in the E-cadherin-
GFP mouse could help us to understand this largely unexplored
area of the metastatic cascade in a spatiotemporal and pre-clin-
ical manner by allowing us to follow E-cadherin dynamics in both
primary and secondary sites in the same mouse.
We focus on the application of FRAP in this study. However,
other imaging techniques such as FLIP or anisotropy imaging
of homo-FRET could also be employed in the future using the
E-cadherin-GFPmouse to address more fundamental questions
regarding E-cadherin regulation at distinct points in the
membrane in situ (Levitt et al., 2015; Roberti et al., 2011).
Furthermore, for fine-tuned assessment of E-cadherin via the en-
dogenous E-cadherin promoter, engineering of a knockin E-cad-
herin-GFP mouse is currently underway as a next-generation
mouse. Therefore, subtle changes to both E-cadherin levels
and mobility could be monitored simultaneously during disease
progression in cancers that also modulate E-cadherin expres-
sion. This could avoid any potential caveats or off-target effects
caused by wrong lineage expression and could circumvent any
minor changes to physiology that may have gone undetected
in our model. Endogenous knockin strategies have been
employed recently to examine the intricate dynamics of other
cell-cell junction types in situ via the recent generation of
ZO-1-GFP mice (Foote et al., 2013). Here, in line with our current
work on adherens junctions, the authors report fundamental dif-
ferences in tight junction dynamics in epidermal tissue in vivo,
which cannot be recapitulated using 2D culture as a surrogate
for living tissue. However, others have shown that E-cadherin
can be differentially regulated within distinct points on the mem-
brane, which could potentially be associated with zona adherens
crosstalk (Priya et al., 2013).
In conclusion, FRAP in the E-cadherin-GFP mouse provides a
flexible approach to monitor the intricate control of E-cadherin
junctions in distinct biological processes in a time-, location-,
and signaling-specific context. Future applications of this mouse
as a tool alone or in combination with deficiencies of E-cadherin
regulators and other tight junction components will profoundly
expand our insights into the networks that govern E-cadherin re-
sponses in developmental, normal, or disease states while guid-
ing therapeutic intervention strategies aimed at targeting cell-cell
junctions during disease progression.CEXPERIMENTAL PROCEDURES
Generation of E-cadherin-GFP Mice
A cDNA encoding EGFP-linked E-cadherin fusion protein (Lock and Stow,
2005) was cloned into pHPRT.CAAG.STOP downstream of a lox-stop-lox
cassette, and the transgene was recombineered into pSKB1 (Bronson et al.,
1996) to generate the final targeting vector. Upon germline transmission, the
lox-stop-lox-E-cadherin-GFP mice (OFF mice) were bred with tissue-specific
Cre driver lines or with CMV-Cre ‘‘deleter’’ mice to generate E-cadherin-GFP
ON mice with ubiquitous E-cadherin-GFP expression.
All animal work was carried out under the control of the British Home Office
and the local Animal Welfare and Experimental Ethics Committee (Cancer
Research UK Beatson Institute and the Garvan Institute of Medical
Research/St. Vincent’s Hospital Animal Ethics Committee).
Confocal Photobleaching Experiments in Cell Culture, Cell-Derived
Matrix and In Vivo
Confluent cells were imaged on 35-mm glass bottom dishes at 37C and 5%
CO2 using a Leica DMI 6000 SP8 confocal microscope or an Olympus FV1000
confocal microscope with a SIM scanner (Serrels et al., 2009). For photo-
bleaching (FRAP, FLIP) experiments in live xenograft tumors, mice were anes-
thetized using a combination of 1:1 hypnorm - H2O + 1:1 hypnovel - H2O, and
the subcutaneous tumor was exposed surgically via a skin flap procedure
(Serrels et al., 2009) on a 37C heated stage. Mice were sacrificed within
4 hr of imaging.
Detailed protocols can be found in the Supplemental Experimental
Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and seven movies and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2015.12.020.
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